Jianjia

Hangzhou Jianjia Medical Technology, formerly known as Jianjia Robot, was one of the first Chinese companies to commercially deploy domestically developed joint replacement surgical robots. Established in 2018, the company has built a hard-tissue surgical robot platform spanning orthopedics and dentistry, positioning its ARTHROBOT and THETA systems against imported alternatives in the Chinese market.

Company Overview

Jianjia Medical focuses on the research, development, and commercialization of surgical robots for hard tissue procedures. The company emerged from a period when China’s joint replacement robot market was dominated entirely by imported systems, primarily Stryker’s Mako platform. Through independent innovation, Jianjia developed its proprietary seven-axis robotic arm technology and achieved regulatory approval ahead of most domestic competitors.

The company’s technical foundation rests on five core competencies: surgical planning, navigation and positioning, 3D visualization, robotic arm control, and system integration. These technologies enable surgical precision within 1mm positional error and 1° angular deviation, addressing the clinical challenges of inconsistent outcomes and steep learning curves associated with traditional joint replacement procedures.

Jianjia attracted significant venture capital attention during China’s medical robotics investment boom. Investors include Hillhouse Capital (Gaoli Ventures), Fosun Pharmaceutical, Baidu Ventures, and LYFE Capital. Hillhouse has publicly described Jianjia as a leading domestic orthopedic robot company with exceptional organizational efficiency and R&D capabilities.

Core Products

ARTHROBOT Joint Replacement Surgical Robot

The ARTHROBOT series represents Jianjia’s flagship product line for orthopedic joint surgery. The platform uses a seven-axis robotic arm configuration and has received multiple NMPA approvals:

• Hip Replacement System (April 2022): First domestically developed hip replacement robot to receive Class III medical device registration, designated as an innovative medical device
• Knee Replacement System (January 2023): Extended the platform to total knee arthroplasty
• Hip-Knee Multi-Application System (August 2023): Consolidated system supporting both hip and knee procedures on a single platform

The ARTHROBOT system covers the complete surgical workflow from preoperative planning through intraoperative execution to postoperative assessment. Clinical studies published in peer-reviewed journals demonstrate improved component positioning accuracy compared to conventional surgical techniques.

THETA Dental Implant Robot

Approved by NMPA in October 2023, THETA is China’s first cantilever-integrated dental implant robot. The system combines robotic arm technology with digital dentistry, featuring integrated binocular vision cameras and touchscreen interface on a compact mobile cart. THETA assists throughout the implant workflow, from preoperative imaging analysis and 3D reconstruction to intraoperative navigation and precise implant placement.

YOZX Full Orthopedic Surgical Robot

The company’s next-generation platform, YOZX, received NMPA approval in September 2024. This system expands Jianjia’s orthopedic coverage beyond joint replacement to include spine and trauma applications, positioning the company to compete across the broader orthopedic robot market.

Technology & Innovation

Jianjia’s seven-axis robotic arm distinguishes its platform from competing systems. The additional degree of freedom enhances surgical accessibility and flexibility, particularly valuable in the confined anatomical spaces of hip and dental procedures. The company holds extensive intellectual property in robotic control algorithms, surgical navigation, and safety boundary systems.

The optical positioning system enables real-time tracking of surgical instruments and implant components, while proprietary planning software generates patient-specific surgical protocols based on preoperative imaging. Safety boundary control prevents the robotic arm from exceeding predetermined safe zones, protecting critical anatomical structures.

Market Presence

As of late 2022, Jianjia held approximately 20% of China’s installed joint replacement robot market, ranking second only to Stryker. In the incremental market (new installations), domestic brands including Jianjia captured 41.67% market share, signaling accelerating import substitution.

The company’s ARTHROBOT systems have been installed in multiple hospitals across China through public tender processes, with average contract values around ¥8-9 million per unit. Partnering with Fosun Pharmaceutical’s subsidiary Chindex, a distributor of da Vinci systems in China, provides Jianjia access to established hospital relationships and sales channels.

IPO History

Jianjia submitted its prospectus to the Shanghai Stock Exchange in 2023, seeking listing on the Science and Technology Innovation Board (STAR Market). The IPO process attracted regulatory scrutiny regarding market size assumptions and commercialization timelines for surgical robots. In September 2024, the company withdrew its listing application, concluding a 17-month review process. The company remains privately held with continued venture capital backing.

Key Milestones

• 2018: Company founded in Hangzhou
• 2020: Completed Series B financing exceeding ¥100 million
• 2021: ARTHROBOT hip robot entered innovative medical device review pathway
• 2022: First domestic hip replacement robot approved (April)
• 2023: Knee robot approved (January), hip-knee multi-application system approved (August), THETA dental robot approved (October)
• 2024: YOZX full orthopedic robot approved (September); withdrew STAR Market IPO application

Frequently Asked Questions

What procedures can ARTHROBOT perform?

ARTHROBOT supports total hip arthroplasty (THA) and total knee arthroplasty (TKA). Indications include primary and secondary osteoarthritis, avascular necrosis of the femoral head (Ficat/ARCO Stage III-IV), rheumatoid arthritis affecting the hip or knee, ankylosing spondylitis, and displaced femoral neck fractures in elderly patients.

How does Jianjia compare to Stryker Mako?

Both systems provide robotic assistance for joint replacement surgery with preoperative planning and intraoperative navigation. Jianjia’s ARTHROBOT uses a seven-axis arm versus Mako’s configuration, potentially offering different maneuverability characteristics. Price positioning favors domestic systems, with ARTHROBOT contract values typically below imported alternatives, aligning with China’s healthcare cost containment policies.

Is Jianjia publicly traded?

No. Jianjia attempted to list on Shanghai’s STAR Market but withdrew its IPO application in September 2024. The company remains venture-backed with investors including Hillhouse Capital and Fosun Pharmaceutical.